Abstract
New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT